

RESEARCH ARTICLE

Genetic and cellular sensitivity of *Caenorhabditis elegans* to the chemotherapeutic agent cisplatin

Francisco Javier García-Rodríguez^{1,2}, Carmen Martínez-Fernández¹, David Brena¹, Dmytro Kukhtar¹, Xènia Serrat¹, Ernest Nadal³, Mike Boxem⁴, Sebastian Honnen⁵, Antonio Miranda-Vizuete⁶, Alberto Villanueva^{2,*} and Julián Cerón^{1,*}

ABSTRACT

Cisplatin and derivatives are commonly used as chemotherapeutic agents. Although the cytotoxic action of cisplatin on cancer cells is very efficient, clinical oncologists need to deal with two major difficulties, namely the onset of resistance to the drug and the cytotoxic effect in patients. Here, we used *Caenorhabditis elegans* to investigate factors influencing the response to cisplatin in multicellular organisms. In this hermaphroditic model organism, we observed that sperm failure is a major cause of cisplatin-induced infertility. RNA sequencing data indicate that cisplatin triggers a systemic stress response, in which DAF-16/FOXO and SKN-1/NRF2, two conserved transcription factors, are key regulators. We determined that inhibition of the DNA damage-induced apoptotic pathway does not confer cisplatin protection to the animal. However, mutants for the pro-apoptotic BH3-only gene *ced-13* are sensitive to cisplatin, suggesting a protective role of the intrinsic apoptotic pathway. Finally, we demonstrated that our system can also be used to identify mutations providing resistance to cisplatin and therefore potential biomarkers of innate cisplatin-refractory patients. We show that mutants for the redox regulator *trxr-1*, ortholog of the mammalian thioredoxin reductase 1 *TRXR1*, display cisplatin resistance. By CRISPR/Cas9, we determined that such resistance relies on the presence of the single selenocysteine residue in *TRXR-1*.

This article has an associated First Person interview with the first author of the paper.

KEY WORDS: *Caenorhabditis elegans*, RNA-seq, Cisplatin

¹Modeling human diseases in *C. elegans*. Genes, Diseases and Therapies Program, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. ²Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, 08908 Barcelona, Spain. ³Thoracic Oncology Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. ⁴Division of Developmental Biology, Department of Biology, Faculty of Science, Utrecht University, 3584 CH Utrecht, The Netherlands. ⁵Heinrich Heine University Düsseldorf, Medical Faculty, Institute of Toxicology, D-40225 Düsseldorf, Germany. ⁶Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, E-41013 Sevilla, Spain.

*Authors for correspondence (avillanueva@iconcologia.net; jceron@idibell.cat)

 F.J.G., 0000-0001-9933-1990; C.M., 0000-0003-1544-4387; D.B., 0000-0003-3318-5120; A.V., 0000-0002-4164-6671; J.C., 0000-0003-4739-2243

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

Received 8 January 2018; Accepted 10 April 2018

INTRODUCTION

The US Food and Drug Administration approved the use of cisplatin [CDDP, cis-diammine-dichloroplatinum(II)] as a chemotherapeutic agent in 1978. Since then, cisplatin and other platinum-based derivatives have been used successfully in cancer treatment. To illustrate their impact in the clinic, it has been estimated that approximately half of all patients undergoing chemotherapeutic treatment receive a platinum drug (Galanski, 2006). Cisplatin exerts activity against a wide spectrum of solid neoplasms, including testicular, bladder, ovarian, head and neck, gastric and lung cancers (Dasari and Bernard Tchounwou, 2014). Strikingly, testicular cancer was previously fatal, but treatment with cisplatin provided a cure for 80% of the patients (Gonzalez-Exposito et al., 2016). Despite its effectiveness, there are patients intrinsically resistant to cisplatin-based therapies, and an important fraction of tumors eventually develop chemoresistance (Amable, 2016).

Cisplatin is composed of a double-charged platinum ion surrounded by four ligands, two amines and two chlorides. Inside cells, the low chloride concentration facilitates cisplatin aquation, replacing chloride groups by water molecules. This process produces a hydrolyzed (or aquated) form of cisplatin that is a potent electrophile (attracted to electrons) that can react with any nucleophile, including nucleic acids and the sulfhydryl groups of proteins (Kelland, 2007).

Cisplatin activity has an impact in the nucleus and in the cytoplasm. In the nucleus, cisplatin produces DNA intra- and interstrand crosslinks that lead to apoptosis (Kelland, 2007). In the cytoplasm, owing to its electrophilic activity, cisplatin behaves as an oxidant (loss of electrons results in oxidation), binding to proteins, including mitochondrial proteins, and especially to thiol groups (-SH). Thus, cisplatin produces a reactive oxygen species homeostasis imbalance that leads to more oxidizing conditions, which violate normal cellular function and, ultimately, can also promote apoptosis (Wang and Lippard, 2005). As a result of its broad and unspecific mode of action, cisplatin also affects normal cells. Nephrotoxicity, neurotoxicity and ototoxicity are some of the dose-limiting side effects reported upon cisplatin therapy (Kelland, 2007). Nevertheless, the major obstacle for the clinical efficacy of cisplatin as an anticancer drug is the chemoresistance developed by tumors rather than its toxicity in normal cells.

The acquisition of cisplatin resistance is multifactorial. The mechanisms by which tumor cells become resistant to the action of cisplatin have been classified into three types (Galluzzi et al., 2014): (1) pre-target mechanisms, i.e. reducing intracellular accumulation of cisplatin or increasing sequestration of cisplatin by nucleophilic scavengers as glutathione (GSH), metallothioneins and other cysteine-rich proteins; (2) on-target mechanisms, i.e. acquiring the ability to repair adducts or becoming tolerant to unrepaired DNA lesions; and (3) post-target mechanisms, i.e. hampering the execution of apoptosis in response to DNA damage (Siddik, 2003).

Caenorhabditis elegans is a well-established organism for the study of signaling pathways in response to drug exposure (Kaletta and Hengartner, 2006). Previous studies, performed in distinct biological contexts (Hemmingsson et al., 2010; Collis et al., 2006), have revealed the value of *C. elegans* to identify genes related to the cisplatin response (Table S1). Here, we show, for the first time, that cisplatin in *C. elegans* produces DNA adducts and a systemic response driven by two conserved transcription factors. We have uncovered a sperm-specific sensitivity to cisplatin and have demonstrated that resistance of the nematode to cisplatin relies on the presence of a single selenocystein of the thioredoxin reductase TRXR-1. Thus, this report is a more comprehensive study of the global response of *C. elegans* to cisplatin that also establishes a reliable methodology for future studies on mechanisms of resistance to cisplatin that would continue contributing to the search for new targets and markers for the benefit of cisplatin-based therapies.

RESULTS

A reliable assay to study the effect of cisplatin in *C. elegans*

In *C. elegans* nematodes, cisplatin produces a wide variety of phenotypes depending on the concentration, length of treatment and developmental stage of the treated animals (Tables S1 and S2).

To implement a reliable methodology and systematically investigate the response of *C. elegans* to cisplatin, we established dose–response patterns during larval development, when cell divisions occur in somatic and germ cells. We exposed a synchronized population of L1 larvae on nematode growth medium (NGM) plates to different cisplatin concentrations for 96 h. We observed effects ranging from a developmental delay at 50 $\mu\text{g}/\text{ml}$ to a larval arrest at 200 $\mu\text{g}/\text{ml}$ (Fig. 1A). Based on this assay, we concluded that body length at 48 h post-L1, upon cisplatin exposure from 50 to 75 $\mu\text{g}/\text{ml}$, is a reliable indicator of the effect of cisplatin during *C. elegans* development (Fig. 1B). Thus, we established a methodology to investigate how distinct treatments or gene activities can influence the response of *C. elegans* to cisplatin.

Transcriptional response of *C. elegans* to cisplatin

To explore the global response of nematodes to cisplatin, we studied transcriptional signatures in RNA sequencing (RNA-seq) experiments. We performed this new transcriptome analysis using a mixed-stage nematode population that was treated for 24 h with 60 $\mu\text{g}/\text{ml}$ of cisplatin, because this dosage of cisplatin produces some phenotypes, but does not compromise the viability of the animals. To reduce the number of false positives, we used two




Fig. 1. Dose–response effect of cisplatin on *C. elegans* development and RNA-seq of animals exposed to cisplatin. (A) Effect of distinct concentrations of cisplatin on larval development. Synchronized L1 larvae were grown on agar plates and exposed to different doses of cisplatin for 96 h at 20°C. Body length values represent mean and SD ($n=50$) of two different experiments. (B) Body length of nematodes that were grown from L1 stage exposed to different doses of cisplatin for 48 h at 20°C. Bars represent mean and SD of three independent replicates ($n=50$, $N=3$). (C) Schematic representation of transcriptomic analyses. Wild-type *C. elegans* from mixed stages were cultured with and without cisplatin (60 $\mu\text{g}/\text{ml}$) for 24 h at 20°C. Then, total mRNA of two biological replicates was purified and sequenced. Volcano plot represents genes significantly up- and downregulated ($P<0.01$) in cisplatin-treated versus untreated animals. (D) Color code represents the functional categories of up- or downregulated genes. Genes were clustered according to the gene functional classification tool DAVID and GO terms retrieved from WormBase.

biological replicates to compare the transcriptomes of treated and non-treated populations (Fig. 1C). We used the Cufflinks algorithm (Trapnell et al., 2012) to process the RNA sequencing data and study differential expression of genes. We identified a set of 83 genes upregulated and 78 genes downregulated by cisplatin in both experiments ($P \leq 0.05$; Table S3). A more restricted list of candidates, using a cut-off P -value of ≤ 0.01 , included 28 genes upregulated and 29 downregulated upon cisplatin exposure.

To explore the functions of these 57 genes, we performed a gene ontology (GO) analysis and identified predicted protein domains (COG) (Tatusov et al., 2003; Huang et al., 2009) (Fig. 1D). Genes encoding CUB-like domains, C-type lectins and glutathione-S-transferases were found among the genes upregulated upon cisplatin exposure. In *C. elegans*, the expression of such genes is associated with detoxification, redox balance, stress response and innate immune system, and it is often regulated by the transcription factors DAF-16 and SKN-1 (Singh and Aballay, 2009; Park et al., 2009; Yen et al., 2011; Tepper et al., 2013) (Table S4). We also detected an overlap with genes induced upon ionizing radiation (IR) (Greiss et al., 2008; Schumacher et al., 2005a,b) (Table S4). Among those, we found genes involved in the apoptotic signaling cascade, including *egl-1* and *ced-13* (Greiss et al., 2008). However, as described below, these two genes function in a distinct manner upon cisplatin exposure.

Of the 29 genes downregulated by cisplatin, we found that most of those were sperm-specific genes (Ortiz et al., 2014), with the Major Sperm Protein (MSP) domain as the most frequent GO annotation (Table S5). Therefore, the reduced brood size induced by cisplatin might be provoked, at least in part, by a specific effect of this agent on spermatogenesis and/or on sperm activity.

Cisplatin reduces the germ cell pool and affects sperm functionality

Our transcriptome analyses indicated that male germline genes are particularly downregulated in the presence of cisplatin. To investigate the effect of cisplatin on the germline, we exposed L4 animals to cisplatin for 24 h, because the switch from spermatogenesis to oogenesis occurs at this stage and therefore both processes can be affected (Ellis and Schedl, 2007). As expected, we observed a dose-dependent reduction of the brood size upon cisplatin exposure (Meier et al., 2014) (Fig. 2A). This reduction was correlated with an increase in the number of unfertilized eggs laid (Fig. 2A) and a decrease in the number of cells at the proliferative region of the germline (Fig. 2B). We observed that cisplatin-treated germlines displayed fewer nuclei in the mitotic region that appeared to be bigger (Fig. 2C), which is an effect described in germlines exposed to DNA-damaging agents that is attributable to cell cycle arrest upon activation of the S-phase checkpoint (Gartner et al., 2004).

The increased number of unfertilized oocytes is a phenotypic hallmark of sperm failure in *C. elegans* (Kadandale and Singson, 2004). To investigate whether the unfertilized oocytes observed upon cisplatin treatment were the result of defective sperm, we crossed cisplatin-treated hermaphrodites with untreated males. We observed that sperm from untreated males rescued, at least in part, the brood size and abrogated the presence of unfertilized oocytes (Fig. 2D). These results suggest that the excess of unfertilized oocytes is attributable to the effect of cisplatin in spermatogenesis rather than in oogenesis.

To investigate the effect of cisplatin on sperm functionality, we used the female/male strain *fog-2(oz40)*, allowing the treatment of males and females independently before the cross. *fog-2(oz40)*

females exposed to cisplatin and crossed with *fog-2(oz40)* untreated males showed a reduced brood size, as expected from the effect of cisplatin on mitotic cells, but we did not detect an increased production of unfertilized oocytes (Fig. 2E). On the contrary, by crossing *fog-2(oz40)* males exposed to cisplatin with untreated *fog-2(oz40)* females we observed a stronger reduction of the progeny, but also a higher number of unfertilized oocytes. These results confirm that, at a similar dose, cisplatin does not hamper the capacity of oocytes to be fertilized but affects the capability of sperm to fertilize.

In summary, the exposure to cisplatin produces smaller germlines as consequence of a reduction of the proliferative region and fertilization problems caused by the effect of cisplatin in the sperm (Fig. 2F).

DAF-16 and SKN-1 are key players in the response to cisplatin

The abundance of *dod* (*downstream-of-daf-16*) genes and other stress response genes in the list of genes upregulated upon cisplatin exposure led us to study the role of DAF-16 and SKN-1. These are the orthologs of human FOXO3 and NRF2, respectively, and are required for stress resistance in *C. elegans* (Rodriguez et al., 2013). Strikingly, we found that half of the upregulated genes were previously reported as DAF-16 and/or SKN-1 targets (Fig. 3A).

The evolutionarily conserved insulin/insulin-like growth factor signaling (IIS) pathway, through its main transcription factor DAF-16/FOXO, controls many different biological processes and regulates a wide variety of stresses, including starvation, oxidative stress (Honda and Honda, 1999), heavy metal toxicity (Barsyte et al., 2001) and ultraviolet radiation (Murakami and Johnson, 1996). DAF-16 is constitutively expressed and sequestered in the cytoplasm in its phosphorylated form. If the inhibitory phosphorylation is compromised, e.g. by reduced signaling of the DAF-2 receptor tyrosine kinase or stress conditions, DAF-16 will translocate to the nucleus. Using a DAF-16::GFP reporter strain, we observed that DAF-16 nuclear location increased upon cisplatin exposure in a dose-dependent manner (Fig. 3B), confirming the implication of the IIS pathway in the response to cisplatin.

Next, we investigated the extent to which the manipulation of the IIS activity could modify the response of the organism to cisplatin. We observed that *daf-2(e1370)* mutants, which are animals lacking a functional DAF-2/IGF-1-like receptor that constitutively induce DAF-16 nuclear localization (Yen et al., 2011), display resistance to cisplatin during larval development (Fig. 3C). Consistently, *daf-16(mu86)* mutants were hypersensitive to cisplatin (Fig. 3C), highlighting the relevance of DAF-16 nuclear activity in the cellular response to cisplatin.

Differently from *daf-2* and *daf-16*, *skn-1* is an essential gene hampering the use of loss-of-function mutants. To confirm the implication of SKN-1 in the response to cisplatin, we used a GFP reporter for one of its canonical targets, *gst-4*. SKN-1 regulates the stress-induced *gst-4* transcription in the presence of redox active compounds, such as paraquat or heavy metals (Tawe et al., 1998; Roh et al., 2006). In our RNA-seq data, *gst-4* is one of the SKN-1-regulated genes strongly induced by cisplatin, and we validated this result using a *gst-4* transcriptional GFP reporter (Fig. 3D,E). Moreover, using *skn-1* RNA interference (RNAi) we confirmed that the cisplatin induction of *gst-4* expression was *skn-1* dependent and *daf-16* independent (Fig. 3D,E). Thus, by studying the impact of cisplatin in the global gene expression we uncovered a systemic response of the organism that is driven by two conserved transcription factors. The fact that these transcription factors are




Fig. 2. Effect of cisplatin in the germline. (A) Cisplatin reduces brood size and increases the percentage of unfertilized oocytes laid. L4 animals were exposed to cisplatin for 24 h at the indicated concentrations ($n=12$, $N=2$). (B) Cisplatin reduces the number of germ cells in the proliferative region of *C. elegans* germline. Number of cells corresponds to nuclei observed, in a single z-stack, at the proliferative region (50 μm away from the distal end of the gonad) ($n=15$, $N=2$). (C) Representative DAPI staining of young adult germline exposed to cisplatin for 24 h. Right panels show magnification of the germline proliferative region (highlighted area). (D) Impact of cisplatin on fertilization. Cisplatin produces unfertilized oocytes and causes reduced brood size in self-fertilized hermaphrodite worms ('Self'), but this effect is rescued, in part, by crossing cisplatin-treated hermaphrodites with untreated males ('Cross'; $n=12$, $N=2$). *** $P>0.001$, ** $P>0.01$, * $P>0.1$; n.s., non-significant. (E) Cisplatin-induced unfertilized oocytes are caused by defective sperm. *fog-2(oz40)* hermaphrodites do not produce sperm, and mating is necessary to maintain the strain. Cisplatin produces unfertilized oocytes only when males are treated ($n=12$, $N=2$). ** $P>0.01$, * $P>0.1$ compared with female treatment in the same conditions. (F) Schematic diagram to illustrate the effect of cisplatin in the germline: bigger nuclei at the proliferative zone (light blue), defective sperm (red dots) and unfertilized oocytes (blue arrow). Bars show mean and s.e.m., and Student's *t*-test was applied.

effectors of metabolic and environmental signals opens new avenues to regulate the response to cisplatin in multicellular organisms.

The BH3-only protein CED-13 protects against cisplatin

We demonstrate, for the first time, that cisplatin leads to the formation of DNA adducts in *C. elegans* (Fig. 4A) and induces the expression of two apoptosis-related genes, *egl-1* and *ced-13*, which encode BH3-only proteins, which are a subset of the Bcl-2 family that contain only a BH3 domain and promote apoptosis. *egl-1* and *ced-13* are transcriptionally induced upon DNA damage (also upon exposure to UV or IR; Stergiou et al., 2007), and this induction is CEP-1/P53 dependent (Greiss et al., 2008). *Y47G7B.2*, another cisplatin-induced gene in our RNA-seq, encodes a nematode-specific gene that is also upregulated upon DNA damage in a *cep-1*-dependent manner (Greiss et al., 2008). Thus,

the effects of cisplatin on upregulation of apoptotic genes could be attributable to *cep-1*-dependent DNA damage.

egl-1 is required for DNA damage-induced apoptosis in both somatic tissues and the germline (Gartner et al., 2000). We investigated *egl-1* induction upon cisplatin exposure in the soma using a GFP reporter strain (*egl-1p::GFP*). During larval development, only 18 somatic cells of wild-type nematodes undergo apoptosis at the early L2 stage (Lettre and Hengartner, 2006). Strikingly, a 24 h cisplatin treatment in *C. elegans* (from L1 to L2) induced ectopic *egl-1p::GFP* expression that was evident in somatic cells (Fig. 4B,C). Moreover, this cisplatin-induced *egl-1* ectopic expression was, at least in part, *cep-1* dependent (Fig. 4D).

In the canonical DNA damage-induced apoptotic pathway, *cep-1* is upstream of the BH3-only proteins EGL-1 and CED-13. However, *ced-13*, and its downstream gene *ced-3*, have an additional role in the intrinsic apoptotic pathway that promotes




Fig. 3. Role of DAF-16/FOXO and SKN-1/Nrf2 transcription factors in the response to cisplatin. (A) Venn diagrams showing the significant overlap between the genes induced by cisplatin found in our transcriptomic analyses and genes regulated by DAF-16 (Tepper et al., 2013) and SKN-1 (Oliveira et al., 2009). $P < 0.001$ by Fisher's test. (B) Cisplatin induces DAF-16 nuclear translocation. Representative image of L2 larvae carrying a translational GFP reporter of DAF-16 with and without cisplatin (90 $\mu\text{g/ml}$ for 5 h). The graph represents the percentage of synchronized L2 larvae after 5 h of exposure to cisplatin at the indicated concentrations. Bars represent mean and s.e.m. ($n=50$, $N=3$). $**P < 0.01$ relative to untreated worms by Student's t -test. (C) IIS pathway influences the response to cisplatin. Body length of synchronized L1 larvae grown for 4 days in the absence or presence of cisplatin. Worms were grown at 15°C to avoid *daf-2(e1370)* dauer phenotype. The inactivation of the IIS pathway in *daf-2(e1370)* mutants, which keeps DAF-16 constitutively in the nucleus, causes resistance to cisplatin, whereas the *daf-16(mu86)* null mutant increases cisplatin sensitivity. Translesion synthesis polymerase 1 mutant allele *polh-1(if31)* was used as a positive control (Roerink et al., 2012). Bars represent mean and SD ($n=50$). $***P < 0.001$ relative to untreated worms by Student's t -test. (D) Cisplatin-induced activation of *gst-4* is regulated by SKN-1. Representative images of synchronized *gst-4p::GFP* L4/young adult animals grown at 20°C on *daf-16(RNAi)* or *skn-1(RNAi)* bacteria from the L1 stage in the presence or absence of cisplatin. *skn-1(RNAi)* inhibits the cisplatin-induced *gst-4* expression. Worms fed with *gfp* RNAi were used as a positive control. (E) Fluorescence intensity for each condition. Bars represent the mean. Error bars indicate the s.e.m. ($n=30$, $N=2$). $***P < 0.001$ relative to untreated animals by Student's t -test.

protective changes rather than killing damaged irreparable cells (Yee et al., 2014). Accordingly, we found that *ced-13* and *ced-3* mutants were sensitive to cisplatin, whereas two different *cep-1* mutants were not resistant to cisplatin (Fig. 4E,F).

In summary, during *C. elegans* larval development, cisplatin induces the expression of *egl-1* and *ced-13*, but their influence is distinct. Inhibition of the canonical DNA damage-induced apoptotic pathway by using *cep-1* mutants does not produce animals resistant to cisplatin. On the contrary, *ced-13* and *ced-3* mutants are sensitive to cisplatin, underscoring a protective role of the intrinsic apoptotic pathway upon cisplatin exposure in somatic cells.

TRXR-1 activity confers systemic sensitivity to cisplatin

The majority of *C. elegans* genes related to cisplatin response published to date present cisplatin sensitivity if inactivated by RNAi

or mutation (Table S1). The human orthologs of these genes are potential targets of therapies to re-sensitize cisplatin-resistant tumors. Given the clinical importance of identifying refractory patients, we wondered whether our system was also valuable for the study of genes whose inactivation confers resistance to cisplatin. In the clinic, mutations or single nucleotide polymorphisms in these genes could function as predictive markers of cisplatin response. In human cell lines, thioredoxin reductase 1 (TRXR1, also known as TXNRD1) selenocysteine amino acid is a direct target of cisplatin, producing cytotoxic and highly pro-oxidant TRXR1 forms called SecTRAPs, which lead to high redox stress resulting in cell death (Anestál et al., 2008). TRXR1 is one of the few selenoproteins [proteins that include a selenocysteine (SeCys) amino acid] in mammals, but TRXR-1 is the only selenoprotein in *C. elegans* (Li et al., 2012) and, in contrast to mammals, this protein is not essential




Fig. 4. Role of apoptotic pathways in the response of *C. elegans* to cisplatin. (A) Southern blot showing that 1,2-GpG-intrastrand crosslinks are raised upon cisplatin exposure of a *C. elegans* population. There is a dose-dependent accumulation of DNA adducts in the presence of cisplatin. NRK-52E rat cells, in which 1,2-GpG-intrastrand crosslinks are not present (Krüger et al., 2016), were incubated with cisplatin as a positive control. (B) Cisplatin induces *egl-1* ectopic expression in somatic tissues during larval development. Representative images of L2 worms carrying a *egl-1p::GFP* reporter, untreated and treated with cisplatin (60 $\mu\text{g/ml}$ for 24 h at 20°C). (C) Quantification of worms with ectopic *egl-1p::GFP* fluorescence in somatic cells of synchronized L1 larvae grown at the indicated concentrations of cisplatin for 24 h at 20°C. Bars represent mean and s.e.m. of three different experiments ($n=50$). ** $P<0.01$ by Student's *t*-test. (D) *egl-1* ectopic induction in somatic cells requires *cep-1/p53*. Quantification of cells with ectopic *egl-1p::GFP* fluorescence of L1 larvae exposed to 60 $\mu\text{g/ml}$ of cisplatin for 24 h at 20°C in wild-type and *cep-1(gk138)* mutants. Bars represent mean and s.e.m. of three different experiments ($n=50$). *** $P<0.01$ by Student's *t*-test. (E,F) Inactivation of the *cep-1/p53* apoptotic pathway does not increase cisplatin resistance. (E) Body length of L1 larvae of wild-type and distinct mutant alleles grown in cisplatin (60 $\mu\text{g/ml}$) for 48 h at 20°C. Bars represent mean and s.d. ($n=50$). This experiment was performed three times with similar results. (F) Relative values of growth delay were obtained by calculating the percentage of the difference in the body length before and after cisplatin exposure (non-parametric Kruskal–Wallis test, *** $P<0.001$; * $P<0.05$; n.s., non-significant).

for viability (Stenvall et al., 2011). Depletion of *C. elegans trxr-1* does not produce phenotypes in terms of morphology, growth, lifespan, brood size or response to oxidative stress. It is essential only for larval molting when the glutathione reductase gene *gsr-1* is

inactivated in parallel (Stenvall et al., 2011). All these features make *C. elegans* an excellent multicellular system in which to study specifically the role of the SeCys residue in the response to cisplatin.

We tested the robustness of our model by studying the role of thioredoxin reductase 1 (*trxr-1*) in the *C. elegans* response to cisplatin. We used the CRISPR/Cas9 system to produce two endogenous TRXR-1 variants, *trxr-1(cer4[U666C])* and *trxr-1(cer5[U666STOP])*, that change the selenocysteine for cysteine and a STOP codon, respectively (Fig. 5A). In a similar manner to the null mutant *trxr-1(sv47)*, these missense mutations showed larval arrest, attributable to molting defects, in combination with *gsr-1(RNAi)* (Fig. 5B). Strikingly, both the null mutant and the point mutations without the selenocysteine produce resistance to cisplatin (Fig. 5C). Thus, both the developmental function and the capacity to promote cytotoxicity in the presence of cisplatin rely on the presence of the selenocysteine residue.

Therefore, the electrophilic activity of hydrolyzed cisplatin in the presence of selenocysteine might produce cytotoxic SecTRAP forms that are major drivers of the harmful effect of cisplatin on multicellular organisms (Fig. 5D).

We also explored the role of *trxr-1* in sensitizing the animal to cisplatin. We found that *trxr-1(sv47)* confers resistance in germ cells

and in somatic cells. Interestingly, by combining *trxr-1(sv47)* with *daf-2* and *daf-16* mutations, the IIS pathway is epistatic to the *trxr-1* activity on cisplatin resistance (Fig. S1).

DISCUSSION

Despite three decades of clinical use and intense research, greater knowledge is necessary to understand, and ultimately control, the molecular events driving endogenous and acquired resistance to platinum-based chemotherapy (Dilruba and Kalayda, 2016). In this context, model organisms are platforms with growing interest in the study of the molecular, cellular and systemic responses to chemotherapeutic agents, but also to screen for new treatments (Nijman, 2015). Here, we reinforce the use of *C. elegans* to study the complex response of multicellular organisms to cisplatin. The function of *C. elegans* genes in the response to cisplatin has been shown in different biological contexts as adult survival or germline apoptosis (Table S1). After testing some of these contexts, we selected the body length of developmental larvae as a reliable and




Fig. 5. *trxr-1* null and missense mutants are resistant to cisplatin. (A) Representation of the *trxr-1* gene. Blue boxes represent exons, and lines represent introns. The upper line denotes the 1663 bp region deleted in the *sv47* allele. Selenocysteine codon TGA is the third last residue and is represented as Sec. The wild-type sequence of the last four codons and their corresponding amino acids are boxed below. *cer4*[U666C] and *cer5*[U666STOP] Sec-deficient *trxr-1* mutant alleles, edited by CRISPR/Cas9, carry a single substitution in Sec codon (C instead of A or A instead of G) that changes the selenocysteine to cysteine or a premature STOP codon, respectively. (B) Sec-deficient *cer4*[U666C] and *cer5*[U666STOP] alleles, in a similar manner to the *trxr-1* null allele, cause a molting-associated growth arrest when fed with *gsr-1(RNAi)*. Graph shows the quantification of larval arrest of L1 larvae fed with *gsr-1(RNAi)* or control bacteria (empty vector). Bars represent mean and s.d. ($n=50$, $N=2$). (C) *trxr-1(sv47)* null mutant and *cer4*[U666C] and *cer5*[U666STOP] point mutant strains show increased resistance to cisplatin. Body length quantification of synchronized L1 larvae grown on agar plates containing 0 and 60 $\mu\text{g/ml}$ of cisplatin for 48 h at 20°C. Bars represent mean and s.d. ($n=50$). This experiment was performed in triplicate with similar results. *** $P<0.001$ relative to wild-type worms in the same conditions by Student's *t*-test. (D) Schematic diagram of the cytotoxic effect produced by the electrophilic activity of cisplatin when reacting with a selenocysteine present in thioredoxin reductase 1.

scalable system to evaluate the response of the animal to cisplatin. Nematodes are easy to synchronize at the L1 stage, and therefore we can study homogeneous populations during larval development, when somatic and germ cells are in active proliferation and apoptotic pathways functional.

The *C. elegans* germline is diverse in cell types, because it contains mitotic cells, meiotic cells, mature oocytes and sperm. We observed that the effect of cisplatin on fertility and cell cycle arrest in the mitotic germline is similar to that produced by other DNA-damaging insults, such as ionizing or ultraviolet C radiations (Gartner et al., 2004), suggesting a direct action of cisplatin on DNA that is supported by our southwestern blots for DNA adducts (1,2-GpG-intrastrand crosslinks). This cisplatin-induced DNA damage response (DDR) in the *C. elegans* germline has already been documented (van Haften et al., 2006; Meier et al., 2014; Honnen, 2017). In addition, however, we found that defective sperm is a major cause of the reduced *C. elegans* fertility observed upon cisplatin exposure at L4. At this stage, we hit oogenesis only partially, but our experiments with *fog-2* mutants suggest that sperm and oocytes are different in terms of resistance to cisplatin. Interestingly, cisplatin is particularly efficient for testicular tumors and causes a drastic effect on spermatogenesis and sperm in treated patients, but this harmful effect seems to affect primarily the chromatin and is reversible (Bujan et al., 2013). In females with ovarian cancer, cisplatin also affects gametogenesis, producing a reduction of the ovarian reserve (Chang et al., 2015). Detailed experiments need to be performed to gain a better understanding of the step at which gametogenesis is hampered in the presence of cisplatin. In this sense, the hermaphrodite condition of *C. elegans* is a clear advantage to study the effect of any given cisplatin dose on oogenesis and spermatogenesis in the same organism.

Our RNA-seq analyses revealed a transcriptomic signature in the presence of cisplatin. The cisplatin-responsive genes identified could be involved in cell autonomous mechanisms (cells have an individual response to cisplatin uptake) or in non-cell autonomous mechanisms (the effect in certain cells influences distant cells). Given that DNA is damaged by cisplatin, a cell-autonomous response occurs as a checkpoint mechanism to favor DNA repair (Gartner et al., 2004). Nevertheless, the vast majority of genes induced by cisplatin in our experiments are related to general stress responses and the innate immune system, which suggests a coordinated systemic response. According to the deregulated genes, this response has DAF-16 and SKN-1 as major drivers and has similarities to that obtained from nematodes exposed to IR or UV-C (Boyd et al., 2010; Greiss et al., 2008). DAF-16 activation positively regulates a wider spectrum of processes, such as stress resistance, innate immunity and metabolic adaptation (Singh and Aballay, 2009; Murphy and Hu, 2013), whereas the NRF2 *C. elegans* ortholog SKN-1 is an important factor in detoxification and response to oxidative stress, and its downregulation has been associated with hypersensitivity to different stressor agents (Blackwell et al., 2015).

Interestingly, immune and stress reactions upon DNA damage are common in mammals (Ermolaeva and Schumacher, 2013), and similar to what we observed in *C. elegans*, cisplatin induces the nuclear translocation of the DAF-16 homolog FOXO3 (Fernandez de Mattos et al., 2008). Human FOXO proteins are crucial regulators of a multitude of cellular functions (Yang and Hung, 2009), but our results encourage further exploration of the manipulation of the IIS pathway to control the cellular response to cisplatin.

The SKN-1 human ortholog NRF2 regulates the expression of stress-responsive genes, such as SOD and catalases, or phase II

detoxification enzymes, such as glutathione transferases (Kaspar et al., 2009). NRF2 overexpression or hyperactivation provokes a direct effect in acquisition of resistance to a wide spectrum of anticancer drugs in many cancer types (Gañán-Gómez et al., 2013; Kaspar et al., 2009). Accordingly, increased nuclear NRF2 expression has been shown in cisplatin-resistant human bladder cancer samples (Hayden et al., 2014). On the contrary, inhibition of NRF2 sensitizes cisplatin-resistant A549 cells (Hou et al., 2015). These observations are concordant with our findings in *C. elegans*, suggesting that direct or indirect targeting of NRF2 should be explored for cisplatin-combined therapeutic interventions.

Our transcriptomic analyses uncovered the upregulation of *egl-1* and *ced-13*, which are related to apoptosis. Using a *egl-1p::GFP* reporter, we found ectopic expression in somatic cells. The apoptotic pathway in postembryonic somatic cells is not well described and might be different in each somatic cell type. In the canonical view of the DNA damage-induced apoptotic pathway, expression of the effector EGL-1 marks cells destined to die (Nehme and Conradt, 2008), and *cep-1/p53* is upstream (Schumacher et al., 2005a). However, *egl-1p::GFP* is still overexpressed in *cep-1/p53* mutants exposed to cisplatin, indicating that inhibition of the DNA damage-induced apoptotic pathway does not completely protect the animal from cisplatin toxicity. Likewise, blockade of apoptosis in adult worms through *cep-1/p53* inhibition does not have any effect on cisplatin sensitivity (Hemmingsson et al., 2010). Thus, inhibition of the DNA damage-induced apoptotic pathway is not an efficient strategy for animals to hamper the global effect of cisplatin. Nonetheless, expression of *cep-1/p53* seems to be important for the full response to cisplatin, and p53 is required for the cytotoxic effect of cisplatin in human glioblastoma cells (Park et al., 2006).

Surprisingly, we found that *ced-13* upregulation might have a protective role, because *ced-13* mutants are sensitive to cisplatin. Mutants of *ced-3*, a gene that is genetically downstream, are also sensitive to cisplatin. This result fits with the role of *ced-13* in the mitochondrial intrinsic apoptotic pathway that extends *C. elegans* longevity (Yee et al., 2014). It is possible that postmitotic cells, which are irreplaceable, activate *ced-13* activity to protect themselves from cisplatin. The role of *ced-13* might be dependent on the insult levels or vary in distinct cell types, because overexpression of *ced-13* in the soma induces cell death of somatic cells that normally survive (Schumacher et al., 2005a). In concordance with a protective role for *ced-13* and *ced-3*, the activity of these genes appears to protect dopaminergic neurons from the toxicity of an oxidative stress-inducing drug (Offenburger et al., 2018).

Thioredoxin system proteins are key players in many important cellular processes, including the maintenance of redox homeostasis (Arner, 2009; Lu and Holmgren, 2014). Regarding the influence of thioredoxins in the cellular response to cisplatin, in mammalian cells it has been shown that a delicate balance exists between the cytotoxic effect of the direct interaction with cisplatin and the protective effect, maintaining the redox equilibrium (Anestål et al., 2008; Cebula et al., 2015). Studies in cell lines suggest that cisplatin cytotoxicity is promoted by a direct interaction between cisplatin and selenocysteine amino acids, leading to the consequent formation of SecTRAPs (Anestål et al., 2008). We confirmed the cisplatin-induced cytotoxicity of TRXR-1 and, generating two distinct missense mutations by CRISPR/Cas9, we demonstrated that this cytotoxicity relies on the presence of a single selenocystein (Sec) at the C-terminal of the protein. Interestingly, the presence of Cys instead of Sec in TRXR1 can be modulated by the presence of the micronutrient selenium in the diet of rats (Lu et al., 2009).

The multifactorial nature of cisplatin resistance hampers the finding of a unique solution to overcome the resistance of tumors to cisplatin. However, there are many parallels between the response of *C. elegans* and mammals to a cisplatin treatment that would facilitate the study in nematodes of particular genetic, metabolic and environmental factors influencing the resistance to cisplatin. This information would be of great help to identify predictive biomarkers and investigate new drugs to have more effective and personalized cisplatin-based therapies.

MATERIALS AND METHODS

Nematode strains and general methods

Caenorhabditis elegans strains were cultured and maintained using standard procedures (Porta-de-la-Riva et al., 2012; Stiernagle, 2006). The N2 (Bristol) strain was used as wild-type in all experiments, and the following alleles and transgenic strains were used in this study: BS553, *fog-2(oz40)* V; XF132, *polh-1(if31)* III; CB1370, *daf-2(e1370)* III; TJ1, *cep-1(gk138)* I; CE1255, *cep-1(ep347)* I; FX536, *ced-13(tm536)* X; MD792, *ced-13(sv32)* X; VB1414, *trxr-1(sv47)* IV; CER170, *trxr-1(cer4[U666C])* IV; CER171, *trxr-1(cer5[U666stop])* IV; CF1038, *daf-16(mu86)* I; TJ356, *zIs356[daf-16p::daf-16a/b::GFP + rol-6(su1006)]* IV; WS1973, *opIs56[egl-1p::2xNLS::GFP]*; CER192, *cep-1(gk138)* I, *opIs56(egl-1p::GFP)*; and CL2166, *dvIs19[pAF15(gst-4p::GFP::NLS)]* III.

CRISPR/Cas9

To generate the *trxr-1(cer4[U666C])* and *trxr-1(cer5[U666Stop])* point mutation alleles, we targeted a site near the selenocysteine codon with CRISPR/Cas9. To make the sgRNA expression plasmid, we cloned the annealed oligonucleotides into *Bsa*I-digested U6::sgRNA pMB70 (Waijers et al., 2013). Repair templates containing desired modifications were designed by Gibson Assembly Cloning Kit (New England BioLabs) and cloned into the pBSK plasmid (Addgene). Oligonucleotide sequences used to generate the 5' and 3' 1.5 kb overlapping fragments are available on request. Both sgRNA and repair template were verified by sequencing using T4 and M13 primers, respectively. Young adult wild-type animals were injected with 30 ng/μl of sgRNA, 100 ng/μl of repair template, 30 ng/μl of *Peff-3::Cas9* vector (Friedland et al., 2013) and 2.5 ng/μl of *Pmyo-2::tdTomato*. Single fluorescent progeny were isolated and screened for the presence of the mutation by PCR. We finally established and validated homozygous mutant lines by PCR and sequencing.

RNA-sequencing analyses

A mixed population of worms representing all stages and grown in control conditions was exposed to 60 μg/ml of cisplatin. After 24 h at 20°C, cisplatin-treated worms and untreated control animals were washed with M9 buffer to remove bacteria, and total RNA was extracted using the TRIzol method. Total mRNA was subsequently enriched using the mirVana miRNA isolation kit (Ambion) followed by poly-A capture. Library construction and Illumina's HiSeq 2000 technology sequencing was performed following the manufacturer's instructions. Approximately 12 million reads (100 bp length) for each sample were processed and aligned using TopHat software to the *C. elegans* reference genome, version WBcel235.74, to produce BAM files [Gene Expression Omnibus (GEO) database reference GSE111654]. These BAM files were analyzed with the SeqSolve NGS software (Integromics, S.L.), using a false discovery rate of 0.05 and filtering reads displaying multiple mapping sites. SeqSolve uses Cufflinks and Cuffdiff (Trapnell et al., 2012) programs to perform differential gene expression analyses between samples ($P < 0.005$). Expression values were normalized in FPKM (fragments per kilobase of exon per million fragments mapped). Datasets of up- and downregulated genes were generated, comparing the differential gene expression analyses of two independent replicates ($P < 0.01$ and $P < 0.05$).

Cisplatin assay during larval development

A synchronized population of L1-arrested larvae was cultured on NGM plates containing fresh OP50 and 0–200 μg/ml of cisplatin (Sigma). The body length of ≥ 50 worms for each condition was measured at 48, 72 and

96 h at 20°C at the stereomicroscope using NIS-Elements 3.2 imaging system. The subsequent analyses were performed with 60 μg/ml of cisplatin in the same conditions except for assays containing *daf-2(e1370)* strain, which were performed at 15°C, measuring the body length after 4 days of incubation to avoid temperature-related developmental delay. Each assay was done in duplicate, and at least two biological replicates were performed. Nonparametric Student's *t*-test (GraphPad Prism 5) was used to determine the significance of differences in the mean.

Analysis of the effect of cisplatin in the germline

To analyze the effect of cisplatin on the germline, a synchronized population of L4-stage animals grown in standard conditions (39 h at 20°C) was transferred onto NGM plates containing 60 μg/ml cisplatin. After 24 h of incubation at 20°C, worms were washed in PBS and germlines dissected in worms anesthetized with 3 mM of levamisole in PBS, fixed with 4% paraformaldehyde and stained with DAPI (0.6 μg/ml). These stained gonads were photographed using a Nikon ECLIPSE TI-s inverted microscope. For germ cell quantification in the proliferative region, the total number of cells in a single z-stack within 50 μm of the distal end of the gonad was counted. At least 15 germlines were counted for each experiment.

Brood size and unfertilized oocytes

To perform the self-fertilization assays, a synchronized population of L3-stage worms was exposed to NGM plates, with addition of fresh OP50 and 0, 60 or 100 μg/ml of cisplatin for 24 h. A total of 12 worms from each condition were selected onto fresh OP50 plates, counting the progeny and the number of oocytes laid after 3 days. A similar protocol was performed for crossing assays, where we used either a male-enriched population in the case of N2, or the male–female population of the *fog-2(oz40)* allele. After 24 h of exposure to cisplatin, a total of 12 genetic crosses were performed for each condition, placing one hermaphrodite, or female in the case of *fog-2(oz40)*, and four males on fresh OP50 plates, letting them mate and lay progeny for 3 days. This experiment was performed in duplicate. A nonparametric Student's *t*-test was used to determine the significance of differences in the mean.

In vivo intracellular localization of DAF-16

To determine the subcellular localization of DAF-16, a synchronized L2-stage population of worms carrying the DAF-16::GFP transgene (TJ356) was transferred to M9 buffer containing 0, 90 or 180 μg/ml of cisplatin for 5 h at 20°C. Then, the worms were washed in M9 and mounted on a microscope slide containing a 2% agar pad, using a drop of 3 mM levamisole to anesthetize them. We quantified the DAF-16 subcellular localization by considering as 'nuclear' worms showing a mainly nuclear GFP accumulation along the whole body, as shown in Fig. 3B. A total of 50 worms were observed in each one of three independent replicates.

egl-p::GFP expression assays

To determine ectopic *egl-1* expression, a synchronized L1-stage population of *egl-1p::GFP* (WS1973) transgenic nematodes was grown on NGM plates containing fresh OP50 and 60 μg/ml cisplatin plates for 24 h at 20°C. For *in vivo* observation, worms were recovered with M9 buffer, washed and mounted on a microscope slide containing a 2% agar pad, using a drop of 3 mM levamisole to anesthetize them. We used a Nikon ECLIPSE TI-s inverted microscope to quantify the number of cells showing an ectopic GFP signal. These experiments were performed three independent times.

RNAi and in vivo gst-4 expression assay

daf-16 and *skn-1* RNAi clones used in this study were obtained from the ORFeome library (Rual et al., 2004). RNAi by feeding was performed in standard conditions, using NGM plates supplemented with 50 μg/μl ampicillin, 12.5 μg/μl tetracycline and 3 mM IPTG. To analyze *gst-4* induction, a synchronized L1-stage population of *gst-4p::GFP* reporter strain was grown on plates containing the corresponding RNAi clone for 24 h at 20°C. Then, worms were transferred to new RNAi plates including 0 or 60 μg/ml cisplatin for 24 h. Then, worms were recovered with M9 buffer, washed and mounted on a microscope slide containing a 2% agar pad, using a drop of 3 mM levamisole to anesthetize them. A Nikon ECLIPSE TI-s inverted microscope was used for *in vivo* observation, and image analysis

was performed using ImageJ software. Average pixel intensity was calculated by sampling 30 worms in each assay.

Southwestern blot analysis for Pt-DNA adducts

The southwestern blot analysis was performed using DNA extracted from a synchronized population of *C. elegans* after 24 h incubation with or without cisplatin. Genomic DNA (0.5 µg each sample) from *C. elegans* and from NRK-52E rat cells (positive control) was isolated using the DNeasy Blood and Tissue kit (Qiagen), denatured by heating (10 min, 95°C) and cooled on ice. After adding 100 µl ice-cold ammonium acetate (2 M), the DNA was transferred onto a nitrocellulose membrane, which was previously soaked in 1 M ammonium acetate. After washing (1 M ammonium acetate and water), the membrane was baked for 2 h at 80°C before being blocked in 5% non-fat milk in TBS/0.1% Tween 20 overnight at 4°C. Incubation with the primary antibody directed against Pt-DNA adducts (1:2000; Abcam; ab103261) was conducted for 1 h at room temperature. Visualization of the antibody signal was done by chemiluminescence (Bio-Rad ChemiDoc Touch Imaging System). Additionally, the membrane was stained with Methylene Blue (MP Biomedicals) to ensure equal DNA loading.

Genetic interaction with *gsr-1* assay

This procedure was performed as previously described (Stenvall et al., 2011). Five L4 worms of the corresponding genotype were transferred to plates containing *gsr-1(RNAi)* bacteria for 24 h at 20°C. Then worms were transferred to new fresh *gsr-1(RNAi)* plates, allowed to lay eggs for 12 h and then removed. After 3 days at 20°C, larval arrest was analyzed only on day 2 plates.

Acknowledgements

We thank the *Caenorhabditis* Genetics Center (CGC), which is funded by National Institutes of Health Office of Research Infrastructure Programs (P40OD010440), for providing strains. Some of the results of this paper are part of the PhD thesis of the first author, Francisco Javier Garcia-Rodriguez, who defended his thesis at Barcelona University in 2016.

Competing interests

The authors declare no competing or financial interests.

Author contributions

Conceptualization: F.J.G.-R., E.N., A.M.-V., A.V., J.C.; Methodology: F.J.G.-R., C.M.-F., M.B., S.H.; Formal analysis: F.J.G.-R., D.B.; Investigation: F.J.G.-R., C.M.-F., D.B., D.K., X.S., S.H., J.C.; Writing - original draft: F.J.G.-R., J.C.; Writing - review & editing: F.J.G.-R., J.C.; Visualization: J.C.; Supervision: A.M.-V., A.V., J.C.; Funding acquisition: E.N., A.V., J.C.

Funding

This study was supported by grants from the Instituto de Salud Carlos III (ISCIII; PI15/00895 to J.C., PI16/01898 to A.V.), which is co-funded by the European Regional Development Fund/FEDER. The A.V. laboratory was also supported by funding from Ministerio de Economía y Competitividad (BFU2007-67123). M.B. was supported by a Netherlands Organization for Scientific Research (NWO) chemical sciences ECHO grant (711.014.005). E.N. was supported a Sociedad Española de Oncología Médica (SEOM) grant for emerging research groups. F.J.G.-R. was the recipient of a PFIS predoctoral fellowship from ISCIII. A.M.-V. was supported by a grant from Ministerio de Economía y Competitividad (BFU2015-64408-P, co-financed by the European Social Fund) and is a member of the EU-ROS Cost Action of the European Union. J.C., M.B., S.H. and A.M.-V are members of the GENIE EU Cost action. D.B. was recipient of a Consejo Nacional de Ciencia y Tecnología 'al extranjero' fellowship (523048).

Data availability

Raw data and details of RNA-sequencing experiments are available at NCBI GEO, with the reference GSE111654.

Supplementary information

Supplementary information available online at <http://dmm.biologists.org/lookup/doi/10.1242/dmm.033506.supplemental>

References

Amable, L. (2016). Cisplatin resistance and opportunities for precision medicine. *Pharmacol. Res.* **106**, 27-36.
Anestál, K., Prast-Nielsen, S., Cenas, N. and Arnér, E. S. J. (2008). Cell death by SecTRAPs: Thioredoxin reductase as a prooxidant killer of cells. *PLoS ONE* **3**, e1846.

Arnér, E. S. J. (2009). Focus on mammalian thioredoxin reductases—Important selenoproteins with versatile functions. *Biochim. Biophys. Acta* **1790**, 495-526.
Barsyte, D., Lovejoy, D. A. and Lithgow, G. J. (2001). Longevity and heavy metal resistance in *daf-2* and *age-1* long-lived mutants of *Caenorhabditis elegans*. *FASEB J.* **15**, 627-634.
Blackwell, T. K., Steinbaugh, M. J., Hourihan, J. M., Ewald, C. Y. and Isik, M. (2015). SKN-1/Nrf, stress responses, and aging in *Caenorhabditis elegans*. *Free Radic. Biol. Med.* **88**, 290-301.
Boyd, W. A., Crocker, T. L., Rodriguez, A. M., Leung, M. C. K., Wade Lehmann, D., Freedman, J. H., Van Houten, B. and Meyer, J. N. (2010). Nucleotide excision repair genes are expressed at low levels and are not detectably inducible in *Caenorhabditis elegans* somatic tissues, but their function is required for normal adult life after UVC exposure. *Mutat. Res.* **683**, 57-67.
Bujan, L., Walschaerts, M., Moinard, N., Hennebiccq, S., Saia, J., Brugnion, F., Auger, J., Berthaut, I., Szerman, E., Daudin, M. et al. (2013). Impact of chemotherapy and radiotherapy for testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network. *Fertil. Steril.* **100**, 673-680.e2.
Cebula, M., Schmidt, E. E. and Arnér, E. S. J. (2015). TrxR1 as a potent regulator of the Nrf2-Keap1 response system. *Antioxid Redox Signal.* **23**, 823-853.
Chang, E. M., Lim, E., Yoon, S., Jeong, K., Bae, S., Lee, D. R., Yoon, T. K. and Choi, Y. (2015). Cisplatin induces overactivation of the dormant primordial follicle through PTEN/AKT/FOXO3α pathway which leads to loss of ovarian reserve in mice. *PLoS ONE* **10**, 1-16.
Collis, S. J., Barber, L. J., Ward, J. D., Martin, J. S. and Boulton, S. J. (2006). *C. elegans* FANCD2 responds to replication stress and functions in interstrand cross-link repair. *DNA Repair* **5**, 1398-1406.
Dasari, S. and Bernard Tchounwou, P. (2014). Cisplatin in cancer therapy: Molecular mechanisms of action. *Eur. J. Pharmacol.* **740**, 364-378.
Diruba, S. and Kalayda, G. V. (2016). Platinum-based drugs: past, present and future. *Cancer Chemother. Pharmacol.* **77**, 1103-1124.
Ellis, R. and Schedl, T. (2007). Sex determination in the germ line. *WormBook* (ed. The *C. elegans* Research Community). WormBook, doi/10.1895/wormbook.1.82.2.
Ermolaeva, M. A. and Schumacher, B. (2013). The innate immune system as mediator of systemic DNA damage responses. *Commun. Integr. Biol.* **6**, e26926.
Fernandez De Mattos, S., Clardy, J. and Lam, E. W.-F. (2008). FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. *Mol. Cancer Ther.* **7**, 3237-3246.
Friedland, A. E., Tzur, Y. B., Esvelt, K. M., Colaiácovo, M. P., Church, G. M. and Calarco, J. A. (2013). Heritable genome editing in *C. elegans* via a CRISPR-Cas9 system. *Nat. Methods* **10**, 741-743.
Galanski, M. (2006). Recent developments in the field of anticancer platinum complexes. *Recent Patents Anticancer Drug Discov.* **1**, 285-295.
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M. and Kroemer, G. (2014). Systems biology of cisplatin resistance: past, present and future. *Cell Death Dis.* **5**, e1257.
Gañán-Gómez, I., Wei, Y., Yang, H., Boyano-Adánez, M.-C. and Garc, í-Manero, G. (2013). Oncogenic functions of the transcription factor Nrf2. *Free Radic. Biol. Med.* **65**, 750-764.
Gartner, A., Milstein, S., Ahmed, S., Hodgkin, J. and Hengartner, M. O. (2000). A conserved checkpoint pathway mediates DNA damage-induced apoptosis and cell cycle arrest in *C. elegans*. *Mol. Cell* **5**, 435-443.
Gartner, A., Macqueen, A. J. and Villeneuve, A. M. (2004). Methods for analyzing checkpoint responses in *Caenorhabditis elegans*. *Methods Mol. Biol.* **280**, 257-274.
Gonzalez-Exposito, R., Merino, M. and Aguayo, C. (2016). Molecular biology of testicular germ cell tumors. *Clin. Transl. Oncol.* **18**, 550-556.
Greiss, S., Schumacher, B., Grandien, K., Rothblatt, J. and Gartner, A. (2008). Transcriptional profiling in *C. elegans* suggests DNA damage dependent apoptosis as an ancient function of the p53 family. *BMC Genomics* **9**, 334.
Hayden, A., Douglas, J., Sommerlad, M., Andrews, L., Gould, K., Hussain, S., Thomas, G. J., Packham, G. and Crabb, S. J. (2014). The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. *Urol. Oncol.* **32**, 806-814.
Hemmingson, O., Kao, G., Still, M. and Naredi, P. (2010). ASNA-1 activity modulates sensitivity to cisplatin. *Cancer Res.* **70**, 10321-10328.
Honda, Y. and Honda, S. (1999). The *daf-2* gene network for longevity regulates oxidative stress resistance and Mn-superoxide dismutase gene expression in *Caenorhabditis elegans*. *FASEB J.* **13**, 1385-1393.
Honnen, S. (2017). *Caenorhabditis elegans* as a powerful alternative model organism to promote research in genetic toxicology and biomedicine. *Arch. Toxicol.* **91**, 2029-2044.
Hou, X., Bai, X., Gou, X., Zeng, H., Xia, C., Zhuang, W., Chen, X., Zhao, Z., Huang, M. and Jin, J. (2015). 3',4',5',5',7-pentamethoxyflavone sensitizes Cisplatin-resistant A549 cells to Cisplatin by inhibition of Nrf2 pathway. *Mol. Cells* **38**, 396-401.
Huang, D. W., Sherman, B. T. and Lempicki, R. A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44-57.

- Kadandale, P. and Singson, A. (2004). Oocyte production and sperm utilization patterns in semi-fertile strains of *Caenorhabditis elegans*. *BMC Dev. Biol.* **4**, 3.
- Kaletta, T. and Hengartner, M. O., (2006). Finding function in novel targets: *C. elegans* as a model organism. *Nat. Rev. Drug Discov.* **5**, 387-398.
- Kaspar, J. W., Niture, S. K. and Jaiswal, A. K. (2009). Nrf2:INrf2 (Keap1) signaling in oxidative stress. *Free Radic. Biol. Med.* **47**, 1304-1309.
- Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. *Nat. Rev. Cancer* **7**, 573-584.
- Krüger, K., Ziegler, V., Hartmann, C., Henninger, C., Thomale, J., Schupp, N. and Fritz, G. (2016). Lovastatin prevents cisplatin-induced activation of pro-apoptotic DNA damage response (DDR) of renal tubular epithelial cells. *Toxicol. Appl. Pharmacol.* **292**, 103-114.
- Lettre, G. and Hengartner, M. O. (2006). Developmental apoptosis in *C. elegans*: a complex CEDnario. *Nat. Rev. Mol. Cell Biol.* **7**, 97-108.
- Li, W., Bandyopadhyay, J., Hwaang, H. S., Park, B.-J., Cho, J. H., Lee, J. I., Ahnn, J. and Lee, S.-K. (2012). Two thioredoxin reductases, *trxr-1* and *trxr-2*, have differential physiological roles in *Caenorhabditis elegans*. *Mol. Cells* **34**, 209-218.
- Lu, J., Zhong, L., Lönn, M. E., Burk, R. F., Hill, K. E. and Holmgren, A. (2009). Penultimate selenocysteine residue replaced by cysteine in thioredoxin reductase from selenium-deficient rat liver. *FASEB J.* **23**, 2394-2402.
- Lu, J. and Holmgren, A. (2014). The Thioredoxin Superfamily in Oxidative Protein Folding. *Antioxid Redox Signal.* **21**, 457-470.
- Meier, B., Cooke, S. L., Weiss, J., Bailly, A. P., Alexandrov, L. B., Marshall, J., Raine, K., Maddison, M., Anderson, E., Stratton, M. R. et al. (2014). *C. elegans* whole genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. *Genome Res.* **24**, 1624-1636.
- Murakami, S. and Johnson, T. E. (1996). A genetic pathway conferring life extension and resistance to UV stress in *Caenorhabditis elegans*. *Genetics* **143**, 1207-1218.
- Murphy, C. T. and Hu, P. J. (2013). Insulin/insulin-like growth factor signaling in *C. elegans*. *WormBook* 1-43.
- Nehme, R. and Conradt, B. (2008). *egl-1*: a key activator of apoptotic cell death in *C. elegans*. *Oncogene* **27**, S30-S40.
- Nijman, S. M. B. (2015). Functional genomics to uncover drug mechanism of action. *Nat. Chem. Biol.* **11**, 942-948.
- Offenburger, S.-L., Jongasma, E. and Gartner, A. (2018). Mutations in *Caenorhabditis elegans* neuroigin-like *glit-1*, the apoptosis pathway and the calcium chaperone *crt-1* increase dopaminergic neurodegeneration after 6-OHDA treatment. K. A. Caldwell, ed. *PLoS Genet.* **14**, e1007106.
- Oliveira, R. P., Abate, J. P., Dilks, K., Landis, J., Ashraf, J., Murphy, C. T. and Blackwell, T. K. (2009). Condition-adapted stress and longevity gene regulation by *Caenorhabditis elegans* SKN-1/Nrf. *Aging Cell* **8**, 524-541.
- Ortiz, M. A., Noble, D., Sorokin, E. P. and Kimble, J. (2014). A new dataset of spermatogenic vs. oogenic transcriptomes in the nematode *Caenorhabditis elegans*. *G3* **4**, 1765-1772.
- Park, C.-M., Park, M. J., Kwak, H. J., Moon, S. I., Yoo, D. H., Lee, H. C., Park, I. C., Rhee, C. H. and Hong, S. I. (2006). Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. *Int. J. Oncol.* **28**, 119-125.
- Park, S.-K., Tedesco, P. M. and Johnson, T. E. (2009). Oxidative stress and longevity in *Caenorhabditis elegans* as mediated by SKN-1. *Aging Cell* **8**, 258-269.
- Porta-De-La-Riva, M., Fontrodona, L., Villanueva, A. and Cerón, J. (2012). Basic *Caenorhabditis elegans* methods: synchronization and observation. *J. Vis. Exp.* e4019.
- Rodriguez, M. Snoek, L. B., De Bono, M. and Kammenga, J. E. (2013). Worms under stress: *C. elegans* stress response and its relevance to complex human disease and aging. *Trends Genet.* **29**, 367-374.
- Roerink, S. F., Koole, W., Stapel, L. C., Romeijn, R. J. and Tijsterman, M. (2012). A broad requirement for TLS polymerases η and κ , and interacting sumoylation and nuclear pore proteins, in lesion bypass during *C. elegans* embryogenesis. S. Jinks-Robertson, ed. *PLoS Genet.* **8**, e1002800.
- Roh, J.-Y., Lee, J. and Choi, J. (2006). Assessment of stress-related gene expression in the heavy metal-exposed nematode *Caenorhabditis elegans*: a potential biomarker for metal-induced toxicity monitoring and environmental risk assessment. *Environ. Toxicol. Chem.* **25**, 2946-2956.
- Rual, J.-F., Ceron, J., Koreth, J., Hao, T., Nicot, A. S., Hirozane-Kishikawa, T., Vandenhaute, J., Orkin, S. H., Hill, D. E., van den Heuvel, S. et al. (2004). Toward improving *Caenorhabditis elegans* phenome mapping with an ORFeome-based RNAi library. *Genome Res.* **14**, 2162-2168.
- Schumacher, B., Schertel, C., Wittenburg, N., Tuck, S., Mitani, S., Gartner, A., Conradt, B. and Shaham, S. (2005a). *C. elegans ced-13* can promote apoptosis and is induced in response to DNA damage. *Cell Death Differ.* **12**, 153-161.
- Schumacher, B., Hanazawa, M., Lee, M.-H., Nayak, S., Volkmann, K., Hofmann, R., Hengartner, M., Schedl, T. and Gartner, A. (2005b). Translational repression of *C. elegans* p53 by GLD-1 regulates DNA damage-induced apoptosis. *Cell* **120**, 357-368.
- Siddik, Z. H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene* **22**, 7265-7279.
- Singh, V. and Aballay, A. (2009). Regulation of DAF-16-mediated innate immunity in *Caenorhabditis elegans*. *J. Biol. Chem.* **284**, 35580-35587.
- Stenvall, J., Fierro-Gonzalez, J. C., Swoboda, P., Saamarthy, K., Cheng, Q., Cacho-Valadez, B., Arner, E. S. J., Persson, O. P., Miranda-Vizuete, A. and Tuck, S. (2011). Selenoprotein TRXR-1 and GSR-1 are essential for removal of old cuticle during molting in *Caenorhabditis elegans*. *Proc. Natl Acad. Sci. USA* **108**, 1064-1069.
- Stergiou, L., Doukoumetzidis, K., Sandoel, A. and Hengartner, M. O. (2007). The nucleotide excision repair pathway is required for UV-C-induced apoptosis in *Caenorhabditis elegans*. *Cell Death Differ.* **14**, 1129-1138.
- Stiernagle, T. (2006). Maintenance of *C. elegans*. *WormBook* (ed. The *C. elegans* Research Community). *WormBook*, doi/10.1895/wormbook.1.101.1.
- Tatusov, R. L., Fedorova, N. D., Jackson, J. D., Jacobs, A. R., Kiryutin, B., Koonin, E. V., Krylov, D. M., Mazumder, R., Mekhedov, S. L., Nikolskaya, A. N. et al. (2003). The COG database: an updated version includes eukaryotes. *BMC Bioinformatics* **4**, 41.
- Tawe, W. N., Eschbach, M.-L., Walter, R. D. and Henkle-Duhrsen, K. (1998). Identification of stress-responsive genes in *Caenorhabditis elegans* using RT-PCR differential display. *Nucleic Acids Res.* **26**, 1621-1627.
- Tepper, R. G., Ashraf, J., Kaletsky, R., Kleemann, G., Murphy, C. T. and Bussemaker, H. J. (2013). PQM-1 complements DAF-16 as a key transcriptional regulator of DAF-2-mediated development and longevity. *Cell* **154**, 676-690.
- Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L. and Pachter, L. (2012). Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat. Protoc.* **7**, 562-578.
- van Haften, G., Romeijn, R., Pothof, J., Koole, W., Mullenders, L. H. F., Pastink, A., Plasterk, R. H. A. and Tijsterman, M. (2006). Identification of conserved pathways of DNA-damage response and radiation protection by genome-wide RNAi. *Curr. Biol.* **16**, 1344-1350.
- Waaijers, S., Portegijs, V., Kerver, J., Lemmens, B. B. L. G., Tijsterman, M., Van Den Heuvel, S. and Boxem, M. (2013). CRISPR/Cas9-Targeted Mutagenesis in *Caenorhabditis elegans*. *Genetics* **195**, 1187-1191.
- Wang, D. and Lippard, S. J. (2005). Cellular processing of platinum anticancer drugs. *Nat. Rev. Drug Discov.* **4**, 307-320.
- Yang, J.-Y. and Hung, M.-C. (2009). A new fork for clinical application: targeting forkhead transcription factors in cancer. *Clin. Cancer Res* **15**, 752-757.
- Yee, C., Yang, W. and Hekimi, S. (2014). The intrinsic apoptosis pathway mediates the pro-longevity response to mitochondrial ROS in *C. elegans*. *Cell* **157**, 897-909.
- Yen, K., Narasimhan, S. D. and Tissenbaum, H. A. (2011). DAF-16/Forkhead box O transcription factor: many paths to a single Fork(head) in the road. *Antioxid. Redox Signal.* **14**, 623-634.

Gene	Gene function	Consequences of inactivation	Phenotype scored	Reference
<i>gcd-2</i>	Nucleotide excision repair	Sensitivity (to cisplatin)	Embryonic lethality	(Collis et al., 2006)
<i>rpa-2</i>	Double strand break repair	Sensitivity	Embryonic lethality	(van Haften et al., 2006)
<i>mus-101</i>	Double strand break repair	Sensitivity	Embryonic lethality	(van Haften et al., 2006)
<i>drh-3</i>	Double strand break repair	Sensitivity	Embryonic lethality	(van Haften et al., 2006)
<i>emb-4</i>	Double strand break repair	Sensitivity	Embryonic lethality	(van Haften et al., 2006)
<i>rad-51</i>	Double strand break repair	Sensitivity	Embryonic lethality	(van Haften et al., 2006)
<i>pqn-85</i>	Chromatin cohesion	Sensitivity	Embryonic lethality	(van Haften et al., 2006)
<i>nap-15</i>	RNA trafficking	Sensitivity	Embryonic lethality	(van Haften et al., 2006)
<i>nola-3</i>	RNA processing	Sensitivity	Embryonic lethality	(van Haften et al., 2006)
<i>F32D1.5</i>	Signalling	Sensitivity	Embryonic lethality	(van Haften et al., 2006)
<i>helq-1</i>	Interstrand crosslink repair	Sensitivity	Embryonic lethality	(Muzzini et al., 2008)
<i>polq-1</i>	Interstrand crosslink repair	Sensitivity	Embryonic lethality	(Muzzini et al., 2008)
<i>lem-3</i>	DNA damage response	Sensitivity	Embryonic lethality	(Dittrich et al., 2012)
<i>polh-1</i>	Translesion synthesis	Sensitivity	Embryonic lethality	(Roerink et al., 2012)
<i>asna-1</i>	Endoplasmic reticulum stress	Sensitivity	Adult lethality	(Hemmingsson et al., 2010)
<i>daf-2</i>	Insulin/IGF receptor	Resistance	Adult lethality	(Hemmingsson et al., 2010)
<i>enpl-1</i>	Endoplasmic reticulum stress	Sensitivity	Adult lethality	(Natarajan et al., 2013)
<i>xpf-1</i>	Nucleotide excision repair	Sensitivity	Embryonic lethality	(Meier et al., 2014)
<i>parp-1</i>	Double strand break repair	Sensitivity	Adult lethality	(Crone et al., 2015)
<i>oct-2</i>	Organic cationic transporter	Resistance	Germline apoptosis	(Papaluca et al., 2016)
<i>unc-84</i>	Non homologous end joining repair	Sensitivity	Embryonic lethality	(Lawrence et al., 2016)
<i>dvc-1</i>	Covalent DNA-protein crosslink repair	Sensitivity	Embryonic lethality	(Stingele et al., 2016)
<i>fzo-1</i>	Mitochondrial fusion	Sensitivity	Larval growth	(Luz et al., 2017)
<i>eat-3</i>	Mitochondrial fusion	Sensitivity	Larval growth	(Luz et al., 2017)

Table S1. Previous studies on cisplatin in *C. elegans*

Stage	Duration (hours)	Medium	Cisplatin ($\mu\text{g/ml}$)	Phenotypes
L1	48	Solid (NGM)	20-40	<i>Rbs, Emb, Pvu, Uol</i>
			50-100	<i>Ste, Gro, Pvu.</i>
			≥ 100	<i>Lva.</i>
L3	24	Solid (NGM)	≤ 100	<i>Rbs, Emb, Pvu, Uol.</i>
			≥ 200	<i>Ste, Pvu.</i>
L4	4	Liquid (M9)	≤ 200	<i>Rbs, Emb, Uol.</i>
YA	48	Liquid (S-med)	≤ 250	<i>Lav.</i>
			≥ 500	<i>Lav, Let.</i>

Table S2. Phenotypes observed in *C. elegans* upon different cisplatin treatments. Phenotypes are abbreviated as follows: *Rbs* (Reduced brood size), *Emb* (Embryonic lethality), *Pvu* (Protruding vulva), *Ste* (Sterile), *Lav* (Locomotor activity variant), *Let* (lethal), *Gro* (Growth delay), *Uol* (Unfertilized oocytes laid).

Table S3. Excel file containing the list of genes deregulated upon cisplatin exposure. Sheet 1: genes deregulated with a p -value $< 0,05$. Sheet 2: genes deregulated with a p -value $< 0,01$

[Click here to Download Table S3](#)

Sequence name	Gene name	KOG Title or Protein Domain	Log2 fold change	DAF-16 related	SKN-1 related	IR induced
Apoptosis related genes (3)						
R09F10.9	<i>ced-13</i>	Single BH3 domain	33,33	-	-	+
F23B12.9	<i>egl-1</i>	Single BH3 domain	3,33	-	-	+
Y47G7B.2			2,12	-	-	+
Stress response/ innate immune response related genes (22)						
F55G11.6		CUB-like domain	33,33	-	-	-
Y51B9A.8		CC domain / ShKT domain	33,33	+	-	-
C41H7.7	<i>clec-3</i>	C-type lectin / CUB-Domain	4,29	+	-	-
F35E8.8	<i>gst-38</i>	Glutathione S-transferase	3,86	-	+	+
F55G11.2		CUB-like domain	3,75	+	+	+
ZK546.11	<i>gst-30</i>	Glutathione S-transferase	3,04	-	-	-
C32H11.4		CUB-like domain	2,91	+	+	+
C32H11.12	<i>dod-24</i>	CUB-like domain	2,85	+	+	+
F35E12.5		CUB-like domain	2,85	+	+	-
K08F4.7	<i>gst-4</i>	Glutathione S-transferase	2,56	+	+	-
K10C2.3	<i>asp-14</i>	Aspartic peptidase	2,41	-	+	-
W06H8.2		Aldolase-type TIM barrel	2,22	-	-	-
Y39G10AR.6	<i>ugt-31</i>	UDP-glucuronosyl/UDP-glucosyltransferase	2,16	-	+	-
C17H12.6		CUB-like domain	2,15	+	+	+
F37B1.2	<i>gst-12</i>	Glutathione S-transferase	2,15	-	+	-
K10D11.1	<i>dod-17</i>	CUB-like domain	2,06	+	+	+
Y40B10A.6	<i>comt-4</i>	O-methyltransferase, family 3	1,99	+	-	-
C55A6.5	<i>sdz-8</i>	Oxidoreductase activity	1,87	-	-	-
F11G11.3	<i>gst-6</i>	Glutathione S-transferase	1,50	-	+	+
F56A4.2		C-type lectin	1,45	-	-	-
K01D12.11	<i>cdr-4</i>	Glutathione S-transferase-like protein	1,42	-	-	+
F35E12.6		CUB-like domain	1,26	-	-	-
Other genes (3)						
Y108F1.4	<i>math-43</i>	Decapping exoribonuclease	33,33	-	-	-
Y54G2A.48		DUF4473	33,33	-	-	-
R09E10.2			2,96	-	-	-

Table S4. Genes induced by cisplatin.

Genes whose expression was significantly increased in two different experiments after a 60 μ g/ml cisplatin treatment. p -value < 0,01. Columns on the rights indicate if these genes are regulated by DAF-16, SKN-1 or induced by IR according to published literature.

Sequence name	Gene name	KOG Title or Protein Domain	Log2 fold change
Sperm specific genes (20)			
F46A8.9			-33,33
C04G2.3		MSP domain	-1,74
R13H9.2	<i>msp-57</i>	MSP domain	-1,60
ZK354.1	<i>msp-65</i>	MSP domain	-1,60
ZK354.5	<i>msp-51</i>	MSP domain	-1,60
ZK354.4	<i>msp-113</i>	MSP domain	-1,58
C34F11.6	<i>msp-49</i>	MSP domain	-1,45
F32B6.6	<i>msp-77</i>	MSP domain	-1,45
C09B9.6	<i>msp-55</i>	MSP domain	-1,44
F58A6.8	<i>msp-45</i>	MSP domain	-1,41
R13H9.4	<i>msp-53</i>	MSP domain	-1,41
K07F5.2	<i>msp-10</i>	MSP domain	-1,40
ZK354.11	<i>msp-59</i>	MSP domain	-1,40
T13F2.11	<i>msp-78</i>	MSP domain	-1,38
F36H12.7	<i>msp-19</i>	MSP domain	-1,37
K07F5.3	<i>msp-56</i>	MSP domain	-1,37
ZK546.6	<i>msp-152</i>	MSP domain	-1,34
K07F5.1	<i>msp-81</i>	MSP domain	-1,28
ZK1251.6	<i>msp-76</i>	MSP domain	-1,26
R05F9.8	<i>msp-33</i>	MSP domain	-1,23
Other genes (9)			
F07C6.6			-33,33
M110.8			-33,33
Y60A9.3		Zinc finger, CCCH-type	-33,33
ZK666.6	<i>cllec-60</i>	C-type lectin	-2,19
F53G12.9		Glutathione S-transferase	-2,13
F44C4.3	<i>cpr-4</i>	Peptidase C1A	-1,94
W03F9.4		Acyltransferase ChoActase/COT/CPT	-1,72
F09C8.1		Lipase, GDSL	-1,64
F58B3.1	<i>lys-4</i>	Glycoside hydrolase, family 25	-1,50

Table S5. Genes downregulated by cisplatin.

Genes whose expression was significantly decreased in two different experiments upon a 60µg/ml cisplatin treatment. *p*-value<0,01.




Figure S1. Characterization of the resistance to cisplatin in *trxr-1(sv47)* mutant

(A) *trxr-1(sv47)* animals are capable of produce progeny when grown on cisplatin (60µg/ml). (B) The *trxr-1(sv47)* mutations suppresses the ectopic expression of *egl-1p::GFP* induced by cisplatin in the soma. (C) Double mutant strain *trxr-1(sv47); daf-16(mu86)* display sensitivity to cisplatin similar to the single mutant *daf-16(mu86)*. (D) Double mutant strain *trxr-1(sv47); daf-2(e1370)* displays a resistance to cisplatin similar to the single mutant *daf-2(e1370)*.

FIRST PERSON

First person – Francisco Javier García-Rodríguez

First Person is a series of interviews with the first authors of a selection of papers published in *Disease Models & Mechanisms*, helping early-career researchers promote themselves alongside their papers. Francisco Javier García-Rodríguez is first author on ‘Genetic and cellular sensitivity of *Caenorhabditis elegans* to the chemotherapeutic agent cisplatin’, published in DMM. Francisco conducted the research in this article while a PhD student in the lab of Julián Cerón and Alberto Villanueva at Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain. He is now a postdoc at the Andalusian Centre for Developmental Biology (CABD), Seville, Spain, using *C. elegans* as a model to investigate the role of the mitochondrial prohibitin complex in aging.

How would you explain the main findings of your paper to non-scientific family and friends?

In the field of cancer chemotherapy, cisplatin is one of the most widely prescribed drugs and an effective treatment for many cancer types, but unfortunately, some tumors are able to develop resistance to the drug. Despite the amount of information available, the cellular mechanisms behind the acquisition of cisplatin resistance remain elusive. We used *Caenorhabditis elegans*, a tiny transparent worm, as a model to better understand biological responses to cisplatin-based chemotherapy.


What are the potential implications of these results for your field of research?

In this work, we established *C. elegans* as an *in vivo* model to show that many parallels exist between the responses of worms and mammals to cisplatin. This will facilitate the use of worms as a model to study the particular genetic, metabolic and environmental factors influencing cisplatin resistance. In the future, these studies could help to identify predictive biomarkers and potential new drugs to develop more effective and personalized cisplatin-based therapies.

What are the main advantages and drawbacks of the model system you have used as it relates to the disease you are investigating?

Although worms cannot develop tumors in any of their somatic tissues, many essential genes and pathways are highly conserved between humans and worms. This makes it possible to use *C. elegans* as a model to gain insights into the molecular and cellular basis of cancer therapy. Additionally, *C. elegans* genetics allows a wide range of genetic studies, plus the generation of mutant and transgenic lines that can be used to interrogate genetic function and interactions, and perform high-throughput *in vivo* drug and genetic screenings that would be more difficult and time consuming in other model systems such as mammals.

Francisco Javier García-Rodríguez’s contact details: Andalusian Centre for Developmental Biology (CABD), Universidad Pablo de Olavide, Carretera de Utrera km 1, 41013 Sevilla, Spain.
E-mail: fjarrod1@upo.es



Francisco Javier García-Rodríguez

“What took lots of effort a few years ago by mutagenesis or bombardment, can now be accomplished in a few days by CRISPR/Cas9 techniques.”

What has surprised you the most while conducting your research?


How genome editing techniques are evolving in *C. elegans*, without any doubt. What took lots of effort a few years ago by mutagenesis or bombardment, can now be accomplished in a few days by CRISPR/Cas9 techniques. We were lucky to experience the development of this tool first hand.

Describe what you think is the most significant challenge impacting your research at this time and how will this be addressed over the next 10 years?

Cisplatin-based research advances have been notorious during the last few years. However, more work is needed to better dissect the cisplatin mechanism of action. Furthermore, I think the trend in the field of chemotherapy is leaning towards personalized medicine, and so advances in tumor characterization would allow individualized and targeted treatments. In line with this, recent advances in *C. elegans* genome editing are allowing fast and easy generation of worms that reproduce the same genetic alterations found in patients, which allows screening for better alternative individualized therapies. We like to call them ‘avatar worms’.

What changes do you think could improve the professional lives of early-career scientists?

I consider myself lucky because during this period I had the most important two things that, in my opinion, are essential for a young researcher: funding and the support of an involved and accessible



Transgenic worms carrying GFP-tagged transcriptional reporter P_{gst-4} show a positive response when exposed to cisplatin.

principal investigator. But, unfortunately, funding is not always accessible here in Spain, where investment in science is decreasing year after year. Research groups have been forced to disband, or PhD students find that they need to leave their research careers and start, maybe, a promising career as a waiter, which is, in fact, better paid...

What's next for you?

After my PhD, I moved to the Andalusian Centre for Developmental Biology (CABD) in my hometown, Seville, as a postdoctoral researcher where we use *C. elegans* to get new insights into how the mitochondrial prohibitin complex affects aging.

Reference

García-Rodríguez, F. J., Martínez-Fernández, C., Brena, D., Kukhtar, D., Serrat, X., Nadal, E., Boxem, M., Honnen, S., Miranda-Vizuete, A., Villanueva, A. and Cerón, J. (2018). Genetic and cellular sensitivity of *Caenorhabditis elegans* to the chemotherapeutic agent cisplatin. *Dis. Model. Mech.* 11: dmm033506.